Search - tctmd.com

Displaying 1 - 8 of 8

Sort: Relevancy | Date

Desperate for Relief, Long COVID Patients Seek Apheresis, Other Untested Therapies

News Daily News

Desperate for Relief, Long COVID Patients Seek Apheresis, Other Untested Therapies

July 14, 2022

TCTMD’s Top 10 Most Popular Stories for January 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2022

January 31, 2022

USPSTF at Last Takes Tougher Stance on Aspirin in Primary Prevention

News Daily News

USPSTF at Last Takes Tougher Stance on Aspirin in Primary Prevention

October 15, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

October 13, 2021

COVID-19: TCTMD’s Dispatch for October Week 2

News Daily News

COVID-19: TCTMD’s Dispatch for October Week 2

October 11, 2021

Antithrombotics No Help for Stable COVID-19 Outpatients: ACTIV-4b

News Daily News

Antithrombotics No Help for Stable COVID-19 Outpatients: ACTIV-4b

June 22, 2021

Antithrombotic Therapy for COVID-19: Challenges and Lessons for the Future

News Daily News

Antithrombotic Therapy for COVID-19: Challenges and Lessons for the Future

March 17, 2021

Rivaroxaban May Yet Protect After a Hospital Stay: MARINER

News Daily News

Rivaroxaban May Yet Protect After a Hospital Stay: MARINER

June 25, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.